$2.93
-0.22 (-7.00%)
Open$3.08
Previous Close$3.15
Day High$3.27
Day Low$2.85
52W High$44.10
52W Low$1.50
Volume—
Avg Volume84.7K
Market Cap5.45M
P/E Ratio—
EPS$-2.25
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+572.8% upside
Current
$2.93
$2.93
Target
$19.68
$19.68
$12.72
$19.68 avg
$25.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 42.4K | 211.1K | 478.0K |
| Net Income | -6,204,810 | -27,838,130 | -25,168 |
| Profit Margin | -14,677.7% | -13,943.8% | -5.3% |
| EBITDA | -5,818,737 | -27,556,331 | -28,783 |
| Free Cash Flow | — | — | -23,138 |
| Rev Growth | -79.9% | -79.9% | +3.1% |
| Debt/Equity | 2.46 | 2.46 | 0.11 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $250.82 | +0.83% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $417.84 | +0.40% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.14 | +1.67% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $516.44 | -1.77% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $805.97 | +1.00% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.12 | +1.42% | 35.2 | 28.41B |